Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (17370)	4/13/2006 12:07:51 PM
From: Galirayo	Respond to of 23958

[ARBX] That one looks ready again .. the NWX is hitting new intraday Highs .. it should move with the Sector. stockcharts.com bigcharts.marketwatch.com Doji Confirmed today off Horizontal Support. Nice looking Chart Bernard. stockcharts.com

To: Jibacoa who wrote (17370)	4/13/2006 3:59:29 PM
From: Galirayo	Read Replies (1) \| Respond to of 23958

[ALKS] FDA Approved. stockcharts.com Alkermes and Cephalon Receive FDA Approval of Vivitrol(TM) for the Treatment of Alcohol Dependence Thursday April 13, 3:50 pm ET First, Once-Monthly Injectable Medication Provides New Treatment Option Companies to Host Conference Call at 4:30 p.m. EDT CAMBRIDGE, Mass. and FRAZER, Pa.--(BUSINESS WIRE)--April 13, 2006--Alkermes, Inc., (Nasdaq: ALKS - News) and Cephalon, Inc., (Nasdaq: CEPH - News) today announced that the U.S. Food and Drug Administration (FDA) has approved VIVITROL(TM) (naltrexone for extended-release injectable suspension) for the treatment of alcohol dependence. VIVITROL, the first and only once-monthly injectable medication for alcohol dependence, is indicated for alcohol dependent patients who are able to abstain from drinking in an outpatient setting and are not actively drinking when initiating treatment. Treatment with VIVITROL should be used in combination with psychosocial support, such as counseling or group therapy. biz.yahoo.com